In 1998, a live, attenuated tetravalent rotavirus vaccine (RotaShield; Wyeth) was recommended for routine use in infants but was then withdrawn in 1999 after concerns arose suggesting an excess risk of intussusception among infants in the weeks following receipt of vaccine.1,2 As a result, larger prelicensure trials with more than 60 000 infants were performed for a pentavalent rotavirus vaccine (RotaTeq; Merck) and a monovalent rotavirus vaccine (Rotarix; GlaxoSmithKline), neither of which was associated with an increased risk of intussusception.3,4 Trial data led to licensure of both vaccines (RotaTeq, 2006; Rotarix, 2008) and the reintroduction of routine rotavirus vaccination for infants in the United States, with 2007 as the first full year of vaccination efforts. To date, postlicensure surveillance studies in the United States have not detected an increased risk of intussusception among rotavirus vaccine recipients.5,6 In contrast, postlicensure active surveillance studies in 69 hospitals in Mexico and Brazil found a small increased risk of intussusception (1 in 51 000 to 1 in 68 000) for infants receiving the first or second dose of monovalent rotavirus vaccine.7 In addition, a recent study in Australia found an increased risk of intussusception in the weeks following the first dose of rotavirus vaccine but no overall increase in the risk of intussusception for vaccinated children aged 1 to 9 months.8 These concerns about intussusception re-emerge at the same time that rapid national adoption of rotavirus vaccination in the United States9 has been associated with significant reductions in diarrhea-associated outpatient and emergency department (ED) visits10–12 and hospitalizations11–15 during rotavirus seasons. The small but clinically significant increased risk of intussusception now reported from international studies, combined with the widespread adoption of rotavirus vaccine in the United States, raises concern for the possibility of increasing intussusception rates with continuing widespread use of rotavirus vaccine. Given the rare incidence of intussusception, it is plausible that surveillance networks may not have the reach or statistical power to identify significant changes in patterns of this condition. Therefore, we sought to address the following question using national data: Has there been a change in hospitalizations for intussusception in infants after the reintroduction of rotavirus vaccine in the United States? To answer this question, we analyzed publicly available data from 3 different sources to examine intussusception rates over time and to estimate excess cases of intussusception that would be predicted based on available rotavirus vaccination coverage rates and the increased risk found in the recent international studies.